Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Health system performance in OECD countries, 1980-1992. Organization for Economic Cooperation and Development

G J Schieber1, J P Poullier, L M Greenwald

  • 1Health Care Financing Administration's (HCFA's) Office of Research and Demonstrations, Baltimore.

Health Affairs (Project Hope)
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health worker remuneration in WHO Member States.

Bulletin of the World Health Organization·2013
Same author

Medicare risk-adjusted capitation payments: from research to implementation.

Health care financing review·2001
Same author

Favorable selection in the Medicare+Choice program: new evidence.

Health care financing review·2001
Same author

France.

Journal of health politics, policy and law·2000
Same author

Health spending, access, and outcomes: trends in industrialized countries.

Health affairs (Project Hope)·1999
Same author

Risk Adjustment for the Medicare program: lessons learned from research and demonstrations.

Inquiry : a journal of medical care organization, provision and financing·1998
Same journal

IRA Reforms To Medicare Part D Reinsurance Were Associated With Plan Exits And Higher Premiums, 2024-25.

Health affairs (Project Hope)·2026
Same journal

Two Years Of Online Harassment Shook My Faith In Medicine.

Health affairs (Project Hope)·2026
Same journal

Nonprofit Hospital Investments At $300 Billion In 2023 With Rising Complexity, Volatility.

Health affairs (Project Hope)·2026
Same journal

Prior Authorization In Medicare Advantage: Beneficiary Exposure And Plan Disenrollment In 2021.

Health affairs (Project Hope)·2026
Same journal

Share Of Physicians With J-1 Visas Training In The US Increased Steadily, 2016-24.

Health affairs (Project Hope)·2026
Same journal

The Extent Of Gender/Sex Variables Included In Clinical Algorithms Across Medical Specialties.

Health affairs (Project Hope)·2026
See all related articles

The U.S. spends more on healthcare than other industrialized nations, with high inflation and costs. Evidence for good value or equity in the U.S. health system is lacking, despite social factors influencing outcomes.

Area of Science:

  • Health economics
  • Comparative health policy
  • Healthcare system analysis

Background:

  • U.S. healthcare expenditure and its growth rate surpass those of other Western industrialized nations.
  • The U.S. healthcare system exhibits higher inflation and opportunity costs compared to peer countries.
  • Poor U.S. health outcomes like life expectancy and infant mortality may be linked to social issues.

Purpose of the Study:

  • To compare U.S. healthcare expenditure and performance with other industrialized nations.
  • To evaluate the value for money and equity of the U.S. healthcare system.

Main Methods:

  • Comparative analysis of healthcare expenditure data.
  • Assessment of health outcome metrics (life expectancy, infant mortality).
  • Evaluation of economic indicators such as inflation and opportunity costs.

Related Experiment Videos

Main Results:

  • U.S. healthcare spending and its rate of increase are higher than in comparable nations.
  • The U.S. system demonstrates significant excess healthcare inflation and opportunity costs.
  • Quantifiable evidence supporting value for money or equity in U.S. health system performance is limited.

Conclusions:

  • The U.S. healthcare system's high costs and inflation do not translate into superior health outcomes or demonstrable value for money.
  • Further investigation is needed to understand the drivers of poor performance and identify avenues for improvement in equity and efficiency.